Heading into 2026, the biopharma industry faces heightened political, regulatory, and reimbursement uncertainty. This year, the level of policy activism is particularly impactful, shaping how companies approach manufacturing, commercialization, and portfolio strategy.

Combined with ongoing patent cliffs and capital pressures, these forces highlight the need for organizations to rethink their business models and position themselves for long-term resilience.

Mari Serebrov breaks down Numerof’s annual Global Pharma Outlook in her article on BioWorld (subscription required): Stormy year in biopharma forecast